Sánchez PAX, Woog CA, Villanueva JV

Language: Spanish
References: 13
Page: 502-505
PDF size: 398.75 Kb.

ABSTRACT

Introduction: polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. It is a heterogeneous condition marked by hyperandrogenism, anovulation, and/or polycystic ovarian morphology, often linked to metabolic issues such as obesity, insulin resistance (IR), and infertility. Hypothesis: insulin resistance occurs in over 80% of women with PCOS. Objective: to assess the incidence of IR in PCOS patients at a private clinic. Material and methods: a retrospective, cross-sectional, observational study was conducted on women diagnosed with PCOS from January 2021 to December 2023, with available serum glucose and insulin levels. Results: IR was identified in 92.2% of patients (329 women). Conclusions: female hormonal health awareness campaigns are recommended to facilitate the early diagnosis of PCOS and associated metabolic abnormalities, in order to ensure timely and multidisciplinary treatment.

REFERENCES

1. Joham A, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJet al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10 (9): 668-680.

2. Reyes E, Ortega C, Martínez N. Association of obesity and overweightwith the prevalence of insulin resistance, pre-diabetes and clinicalbiochemicalcharacteristics among infertile Mexican women withpolycystic ovary syndrome: a cross-sectional study. BMJ Open. 2016;6 (7): e012107.

3. Rojas R, Aguilar CA, Romero M, Castro L, Gómez D, Mehta R. Trendsin the prevalence of metabolic syndrome and its components inMexican adults, 2006-2018. Salud Publica Méx. 2021; 63 (6): 713-724.

4. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovarysyndrome (PCOS): the hypothesis of PCOS as functional ovarianhyperandrogenism revisited. Endocr Rev. 2016; 37 (5): 467-520.

5. Gilbert E, Tay C, Hiam D, Teede H, Moran L. Comorbidities andcomplications of polycystic ovary syndrome: an overview ofsystematic reviews. Clin Endocrinol (Oxf). 2018; 89 (6): 683-699.

6. Al Wattar BH, Fisher M, Bevington L, Talaulikar V, Davies M, ConwayG et al. Clinical practice guidelines on the diagnosis and managementof polycystic ovary syndrome: a systematic review and qualityassessment study. J Clin Endocrinol Metab. 2021; 106 (8): 2436-2446.

7. Sánchez MA, Tena-Sempere M. Metabolic dysfunction in polycysticovary syndrome: pathogenic role of androgen excess and potentialtherapeutic strategies. Mol Metab. 2020; 35: 100937.

8. Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VLet al. Polycystic ovary syndrome: a “risk-enhancing” factor forcardiovascular disease. Fertil Steril. 2022; 117 (5): 924-935.

9. Belania M, Deoa A, Shahb P, Bankerb M, Singalc P, Gupta S.Differential insulin and steroidogenic signaling in insulin resistantand non-insulin resistant human luteinized granulosa cells-A studyin PCOS patients. J Steroid Biochem Mol Biol. 2018; 178: 283-292.

10. Lagana AS, Garzon S, Casarin J, Franchi M, Ghezzi F. Inositolin polycystic ovary syndrome: restoring fertility through apathophysiology-based approach. Trends Endocrinol Metab. 2018;29 (11): 768-780.

11. Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in thepathogenesis, diagnosis and treatment of PCOS: focus on insulinresistance, inflammation, and hyperandrogenism. Int J Mol Sci. 2022;23 (8): 4110.

12. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and thepolycystic ovary syndrome revisited: an update on mechanisms andimplications. Endocr Rev. 2012; 33 (6): 981-1030.

13. Ortiz-Flores AE, Luque-Ramírez M, Escobar-Morreale HF. Polycysticovary syndrome in adult women. Med Clin (Barc). 2019; 152 (11):450-457.